CureVac Advances Seasonal Flu Study To Phase 2 In Collaboration With GSK Following Selection Of Promising mRNA Vaccine Candidate With Broad Coverage, The Trial Is Expected To Start Dosing In Q4 2023
Author: Benzinga Newsdesk | September 12, 2023 07:20am